1. SLC13A3 is a major effector downstream of activated β-catenin in liver cancer pathogenesis.
- Author
-
Zhao, Wennan, Wang, Xue, Han, Lifeng, Zhang, Chunze, Wang, Chenxi, Kong, Dexin, Zhang, Mingzhe, Xu, Tong, Li, Gen, Hu, Ge, Luo, Jiahua, Yee, Sook Wah, Yang, Jia, Stahl, Andreas, Chen, Xin, and Zhang, Youcai
- Subjects
Humans ,beta Catenin ,Animals ,Liver Neoplasms ,Mice ,Cell Line ,Tumor ,Glutathione ,Gene Expression Regulation ,Neoplastic ,TOR Serine-Threonine Kinases ,Wnt Signaling Pathway ,Leucine ,Proto-Oncogene Proteins c-myc ,Amino Acid Transport System y+ ,Carcinoma ,Hepatocellular ,Male ,Large Neutral Amino Acid-Transporter 1 - Abstract
Activated Wnt/β-catenin pathway is a key genetic event in liver cancer development. Solute carrier (SLC) transporters are promising drug targets. Here, we identify SLC13A3 as a drug-targetable effector downstream of β-catenin in liver cancer. SLC13A3 expression is elevated in human liver cancer samples with gain of function (GOF) mutant CTNNB1, the gene encoding β-catenin. Activation of β-catenin up-regulates SLC13A3, leading to intracellular accumulation of endogenous SLC13A3 substrates. SLC13A3 is identified as a low-affinity transporter for glutathione (GSH). Silencing of SLC13A3 downregulates the leucine transporter SLC7A5 via c-MYC signaling, leading to leucine depletion and mTOR inactivation. Furthermore, silencing of SLC13A3 depletes GSH and induces autophagic ferroptosis in β-catenin-activated liver cancer cells. Importantly, both genetic inhibition of SLC13A3 and a small molecule SLC13A3 inhibitor suppress β-catenin-driven hepatocarcinogenesis in mice. Altogether, our study suggests that SLC13A3 could be a promising therapeutic target for treating human liver cancers with GOF CTNNB1 mutations.
- Published
- 2024